Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.

Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”

The launch of injectable doxercalciferol and FDA approvals for mycophenolic acid delayed-release tablets and betamethasone dipropionate ointment could add some cheer to Lupin whose high-potential launches in the US have seen delays. However, analysts are not very enthused.